Collaboration, License, and Other Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Revenue	$ 97,529	$ 88,845
Collaborative arrangements revenue
Revenues:
Revenue	97,529	88,665
Collaborative arrangement, other agreements
Revenues:
Revenue	480	404
Sale of active pharmaceutical ingredient
Revenues:
Revenue		180
AbbVie | Sale of active pharmaceutical ingredient
Revenues:
Revenue		159
AbbVie | North America | Collaborative arrangements revenue
Revenues:
Revenue	94,901	86,499
AbbVie | North America | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	94,901	86,499
AbbVie | Europe and Other | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	610	600
AstraZeneca | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	192	210
AstraZeneca | Sale of active pharmaceutical ingredient
Revenues:
Revenue		21
Astellas Pharma Inc. | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	523	496
Alnylam | Collaborative arrangement, co-promotion agreements
Revenues:
Revenue	$ 823	$ 456